Spots Global Cancer Trial Database for Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer
Official Title: Evaluate Efficacy and Safety of Serplulimab（HLX10）in Patients With Advanced, Recurrent and Metastatic Cervical Cancer：A Prospective, Multicenter, Non-interventive Real-world Study
Study ID: NCT05883670
Conditions
Interventions
Study Description
Brief Summary: This study is a Prospective, Multicenter, non-interventive Real-world Study to evaluate the efficacy and safety of the treatment of Serplulimab in patients with Advanced,Recurrent and Metastatic Cervical Cancer. Approximately 118 eligible subjects are planned to be enrolled across all sites.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Qilu Hospital of Shandong University, Jinan, Shandong, China
Contact Details
Name: Beihua Kong, MD.PhD.
Affiliation: Qilu Hospital of Shandong University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
